Loading
TR
TELCON RF PHARMACEUTICAL. Inc. Stock: price and insider trades · South Korea
텔콘RF제약
No insider purchase over the last 90 days. The latest, by 에버코어인베스트먼트홀딩스, was filed 16 Jul 2026.
TELCON RF PHARMACEUTICAL. Inc.: what insiders have been doing
Every trade that managers of TELCON RF PHARMACEUTICAL. Inc. disclose to DART (FSS) is tracked on this page. The company sits in the Health Care sector. From 21 October 2025 to 21 October 2026, the disclosure feed for TELCON RF PHARMACEUTICAL. Inc. logged 11 filings by 4 insiders.
Both sides are active: 4 purchases and 5 sales, from 2 insiders and 2 insiders respectively. No amount is published for 9 filings, which the totals therefore leave out. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Among those who bought: 1 major shareholder.
With 11 filings in twelve months, the company is more active than the median of 7 filings across the 2,650 companies we follow on the same exchange. Our records for TELCON RF PHARMACEUTICAL. Inc. go back to 2021, with 5 purchases and 15 sales on the open market in total.
The clock since the last published purchase (16 July 2026) now reads 100 days. Filings reach the DART (FSS) feed a median of 3 days after the trade. Until a filing is published, the market cannot know about the trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Elsewhere in the same sector, our signals recently picked up insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc. Source: insider filings from DART (FSS). Past trades are no guide to future returns.
Insider Decl.
33
Thresholds
n/a
Buy Volume
€56M
5 ops. · all time
Sell Volume
€4B
15 ops. · all time
Who traded when
BuySale뉴온2 buys6 sales
상상인저축은행1 buy1 sale
에버코어인베스트먼트홀딩스2 buys
Since the insiders bought
- +1.0%Entry ₩6,440 · Close at T+90 ₩6,502
- -49.6%Entry ₩700 · Close at T+90 ₩353
- -13.2%Entry ₩11,390 · Close at T+90 ₩9,890
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Fundamental score
Ranked 21,622 of 26,280 companies
28.8
score / 100
Value41
Quality17
FCF yld8.8%
Earn yld-75%
EV/EBITDA·
ROE-33%
Gross mgn24%
Net mgn-27%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
₩2,145
Analyst consensus
Income statement
Revenue₩43.2B
Gross profit₩10.2B24% margin
EBITDA-₩1.8B-4% margin
Net income-₩11.5B-28.3% margin
Valuation
Beta0.38
Balance sheet & cash
Market cap₩15.3B
Total debt₩34.3B
Free Cash Flow₩1.3B
Debt / Equity63%
Profitability & ownership
ROE-32.7%
ROA0.2%
% insiders16.0%
% institutions0.0%
Last declaration on 16 July 2026
Declarations34 total
Other
0DART
2,329,916 sharesKRXDART:20260716000738
Canonical exit: 14 Oct 2026 (T+90)
▼
Executives
0DART
2,989,916 sharesShareKRXDART:20260716000723
Canonical exit: 8 Oct 2026 (T+90)
660,000 sharesShareKRXDART:20260716000713
12,362,844 sharesShareKRXDART:20260630000887
13,943,631 sharesKRXDART:20260630000872
1,849,908 sharesKRXDART:20260610000188
●
Executives
0DART
3,000,000 sharesShareKRXDART:20260417000655
Canonical exit: 16 Jul 2026 (T+90)
3,307,000 sharesKRXDART:20260417000647
Canonical exit: 16 Jul 2026 (T+90)
●
Executives
0DART
7,232,182 sharesKRXDART:20251002000511
Canonical exit: 30 Nov 2025 (T+90)
●
Executives
0DART
●
Executives
0DART
22,207,965 sharesShareKRXDART:20241227000677
304,345 sharesKRXDART:20241227000667
13,586,956 sharesKRXDART:20241111000411
●
Executives
0DART
●
Executives
0DART
●
Executives
0DART
13,586,956 sharesKRXDART:20221104000437
13,586,956 sharesKRXDART:20221007000502
13,586,956 sharesKRXDART:20220506000500
13,586,956 sharesKRXDART:20220429001489
25 of 34 declarations
About TELCON RF PHARMACEUTICAL. Inc.
텔콘RF제약 is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in the development of innovative pharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
